Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches ...

中国国家药品监督管理局 (NMPA)已批准OncoMate® 微卫星不稳定性 (MSI)检测试剂盒作为中国三类体外诊断医疗器械。该试剂盒拟作为伴随诊断试剂，用于识别高微卫星不稳定性 (MSI-H)实体瘤患者，以接受美国新泽西州拉威市Merck & Co., Inc.的抗PD-1疗法——KEYTRUDA ® (pembrolizumab)治疗。这是Promega首款获得NMPA批准的伴随诊断试剂。

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

默沙东集团（Merck & Co）周二公布的第四季度盈利和收入均超过预期，这得益于其癌症免疫疗法Keytruda及一些较新产品需求强劲。 但该公司发布的2026年展望较为保守，未达到华尔街的预期，因为公司正为其几款药物将在今年晚些时候失去专利保护并面临仿制药竞争做准备。这些药物包括2型糖尿病药物Januvia和Janumet，以及帮助恢复手术中被阻断的肌肉功能的药物Bridion。 虽然这些药物不 ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...

Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98.

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...